Tight Glycemic Control by Artificial Pancreas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hyperglycaemia has been repeatedly associated with risk of mortality and morbidity in the intensive care unit (ICU). The evidence currently available is in favour of a 'normal ≤ 6.1 mmol/l' level for blood glucose control in ICUs according to two large randomized control trials of Van den Berghe G and is not supportive of J. Miles's viewpoint in this debate. In this study, the investigators would like to evaluate that the target of blood glucose level, whether is a normal level (80-110 mg/dL) or another level (140-160 mg/dL), should be set for the reduction of perioperative mortality and complications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tight Glycemic Control by Artificial Pancreas

NCT00657995

Pancreatic Neoplasm

COMPLETED NA

Effect of an Artificial Pancreas in Patients Undergoing Hepatic Resection

NCT00659698

Liver Diseases

COMPLETED PHASE4

Automated vs Conventional Perioperative Glycemic Control in Diabetic Patients Undergoing Cardiopulmonary Bypass Surgery

NCT03314272

Diabetes Cardiopulmonary Bypass

COMPLETED NA

Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition

NCT07121504

Type 2 Diabetes

RECRUITING NA

Artificial Pancreas With Carbohydrate Suggestion for Patients With Type 1 Diabetes Prone to Hypoglycemia

NCT05628662

Type 1 Diabetes Mellitus Prone to Hypoglycemia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our previous prospective randomized clinical trial suggested that the postoperative morbidities were reduced by tight glycemic control of a normal level for blood glucose using artificial pancreas. However, the most feared one is hypoglycaemia, which, when severe and prolonged, may cause convulsions, coma and brain damage, as well as cardiac arrhythmias. Recently, Ven den Berghe G report that the development of accurate, continuous blood glucose monitoring devices, and preferably closed-loop systems for computer-assisted blood glucose control in the ICU, will help to avoid hypoglycaemia. In our study, no hypoglycemia showed in more than 100 patients who performed perioperative tight glycemic control by artificial pancreas.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Disease Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.

Group Type ACTIVE_COMPARATOR

Artificial pancreas

Intervention Type DEVICE

Artificial endocrine pancreas (NIKKISO Company)

2

Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.

Group Type ACTIVE_COMPARATOR

Artificial pancreas

Intervention Type DEVICE

Artificial endocrine pancreas (NIKKISO Company)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artificial pancreas

Artificial endocrine pancreas (NIKKISO Company)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

artificial endocrine pancreas (NIKKISO Company)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who were suffering from liver, pancreas or cardio-vascular diseases, were informed of the purpose and details of the study, and written consent was obtained from them prior to enrolment.